Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Again, no buy signal anywhere to be found:
https://www.barchart.com/stocks/quotes/ADMD/opinion
SSDD.
NEXT!
That is a good strategy, but it relies solely on the PPS dipping at the right time, then a decent PR comes out.
Otherwise, the only right strategy, if you have lots of money invested, is to try to market-time your sale(s) to the extent that the PPS manages to creep up a couple of points. The problem is that you cannot make decent money by selling into the bid + be saddled with the 28% STCGT that accompanies each sale. I don't buy it when peeps brag about their actual gains.
http://www.stockta.com/cgi-bin/analysis.pl?symb=ADMD&cobrand=&mode=stock
Doesn't look any better here either. StockTA is a well-respected charting site.
These aren't novice charting websites ... unless their rating for a stock in question is tanking. Funny how perspective changes everything. If Barchart's rating were a strong buy, people would be crowing about it. Regrettably for longs, it is not. Hopefully when you start selling at .0001, there will be buyers waiting.
No buy recommendation as far as the eye can see:
https://www.barchart.com/stocks/quotes/ADMD/opinion
The rating takes into account those few daily prop-ups to keep the PPS from sinking further.
Wow! Someone decided to come in and prop up the stock price by buying a chunk at the ask. That will last a day or so.
https://www.barchart.com/stocks/quotes/ADMD/opinion
https://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ADMD
Strong sell signals on both charting sites. Not looking good at all.
Yeah, right. That's why there is so much attention being given to this. Your opinion only.
Not much. Looks like the dumpfest is well underway today. Getting very close to trip 1's.
Especially with EOY dumping to take write-offs, this should get interesting.
More potential competition for RadioGel. Doesn't explicitly state for cancer, but you can bet that it will be included in these pot med studies. This is going to have a snowball effect IMHO.
Veterinarians Seek Permission To Research Pot Meds For Pets
By ANDREW SELSKY - Associated Press - 43 minutes ago
In this Monday, Oct. 30, 2017, photo, Luke Byerly tends to his 14-year-old beagle, Robbie, during a break at Byerly's job as a technician at a veterinary clinic in east Denver. Byerly is using CBD, a non-psychoactive component of marijuana, oil to treat the dog's arthritis. (AP Photo/David Zalubowski)
BEND, Ore. (AP) — Dr. Byron Maas surveys a supply of marijuana products for dogs that lines a shelf in his veterinary clinic. They're selling well.
"The 'Up and Moving' is for joints and for pain," he explains. "The 'Calm and Quiet' is for real anxious dogs, to take away that anxiety."
People anxious to relieve suffering in their pets are increasingly turning to oils and powders that contain CBDs, a non-psychoactive component of marijuana. But there's little data on whether they work, or if they have harmful side effects.
That's because Washington has been standing in the way of clinical trials, veterinarians and researchers say. Now, a push is underway to have barriers removed, so both pets and people can benefit.
Those barriers have had more than just a chilling effect.
When the federal Drug Enforcement Administration announced last year that even marijuana extracts with CBD and little or no THC - marijuana's intoxicating component - are an illegal Schedule 1 drug, the University of Pennsylvania halted its clinical trials. Colorado State University is pushing ahead.
The U.S. Food and Drug Administration has warned companies that sell marijuana products online and via pet shops and animal hospitals that they're violating laws by offering "unapproved new animal drugs." The FDA threatened legal action.
But, seeing potential benefits of CBDs, the American Veterinary Medical Association's policy-making body said last summer it wants the DEA to declassify marijuana as a Schedule 1 drug "to facilitate research opportunities for veterinary and human medical uses." It asked the board of the national veterinarians' organization to investigate working with other stakeholders toward that goal. The board is awaiting a recommendation from two group councils.
"The concern our membership has is worry about people extrapolating their own dosages, looking to medicate their pets outside the realm of the medical professional," Board Chairman Michael Whitehair said in a telephone interview. "This is an important reason for us to continue the research."
Utah Sen. Orrin Hatch, a conservative Republican, became an unlikely champion of this push when he introduced a bill in September that would open the path for more clinical research. While Hatch said he opposes recreational marijuana use, he wants marijuana-based drugs, regulated by the FDA, produced for people with disorders.
"We lack the science to support use of medical marijuana products like CBD oils, not because researchers are unwilling to do the work, but because of bureaucratic red tape and over-regulation," Hatch said.
Dawn Boothe, of Auburn University's College of Veterinary Medicine, is waiting for federal approval to begin a study of marijuana's effects on dogs with epilepsy. The classification of marijuana products containing CBD as a Schedule 1 drug, the same category as heroin and LSD, creates a "major, major, major, terrible roadblock" for researchers, Boothe said in a phone interview.
Researchers at the University of Pennsylvania School of Veterinary Medicine were studying CBDs' effects on dogs with osteoarthritis and pruritis, or itchiness, until the DEA released its policy statement.
"The ambiguity in this process has really brought us to a screeching halt," said Michael DiGregorio, director of the university's clinical trials center. "It is research that needs to be done, because there are a lot of CBD products out there."
When it clarified that marijuana CBD extracts are Schedule 1 drugs, the DEA said it was assigning a code number to those substances to better track them and to comply with international drug control treaties.
DiGregorio complained that researchers seeking federal approval to study CBD products are told to provide certain data, but that data isn't normally available until the study is done.
"If you don't have the data, you can't get the registration to do the work," he said.
On a recent morning, Maas took a break from seeing four-legged patients in the Bend Veterinary Clinic. A stethoscope dangling from his neck over green scrubs, Maas said his clients have reported CBDs help relieve pain, arthritis, anxiety, loss of appetite, epilepsy and inflammation in their pets.
"Unfortunately there's not a lot of research out there, especially on animals, on CBD compounds," Maas said. "The research is really necessary to help us understand how to actually use these compounds on our pets."
Veterinarian Janet Ladyga of the Blue Sky Veterinary Clinic, also in Bend, said she doesn't recommend marijuana products because of the unknowns.
"We don't have a lot of evidence right now, so we don't know the toxicity or the safety profile ... and we don't have any good evidence to show either if it's safe or efficacious," she said.
The study at Colorado State University aims to provide some data. The roughly two dozen dogs in the arthritis study and the 30 in the epilepsy tests are given either CBD oil or a placebo. For the arthritis study, activity monitors are attached to the animals' collars, to determine if they're more mobile when they're taking CBD.
Principal investigator Stephanie McGrath said she hopes the results will be a stepping stone for longer and more diverse studies, and that they provide useful information for human medicine.
"Every medication we're taking has been given to a dog first," the University of Pennsylvania's DiGregorio noted.
Meanwhile, Boothe said she had everything ready to start her study in January, and was waiting for a green light from federal officials.
"I don't know what's taking so long," she said.
Oh my. Dropping into the trip 2's. This seems to be headed into the grays (adjusted for the untimely r/s). https://www.barchart.com/stocks/quotes/ADMD/opinion
You have your answer, Catfish. Tcsxyz provided it to you here.
You're quite welcome.
Low volume and it is still in the red.
I don't know why they would. The PPS has been mired at or near low trips (adjusted for the untimely R/S) for some time now. Doesn't look to me like it's going anywhere.
Looks like we're at the same point as we were a week ago. Nothing changes with this stinky pinky.
https://www.barchart.com/stocks/quotes/ADMD/opinion
Not really. I have correctly predicted the tanking of the stock price, the continual delays in obtaining FDA approval, the continual delays in getting institutional financing, the continual delays in getting the vet angle off the ground, etc.
SSDD.
Uhh, no.
I don't have a clue what you're talking about. And I did not delete it; an admin did.
The thing about posting how much someone made on the last run does not take into account the STCGT on each and every transaction. Selling takes place at the bid, not the ask. And the stock has taken a vicious pounding since the last run to .0094. Now it's at .0003 adjusted for the R/S. Korenko putting some of his own money in keeps this thing afloat for another few months.
Promises by the CEO have been made a great many times over the past few years. The promise of FDA approval. The promise of the vet angle moving forward. The promise of institutional investors coming forward. None have really panned out, which is why the stock price has been slowing sinking. And Tilltom is spot on when he points to the last filing ... and Tcsxyz has also pointed out ... that the company is still broke and in debt worse than the prior filing. Peeps getting bonus shares (and other investors) have been slowly selling off their positions. But apparently not enough buyers willing to scoop up those shares, which is partially why the stock continues its drop. And still no consensus of what vets are going to have to charge for full treatment once the company is both legally and financially able to distribute a nuclear-based cancer product. And only one feline has been treated so far.
This company is still way off satisfying most serious investors with their progress. Sure, maybe some individual ones here and there, but not the big whales yet, despite the R/S which was done entirely for this purpose.
https://www.barchart.com/stocks/quotes/ADMD/opinion
88% STRONG SELL
Nothing has materially changed.
LMFAO!! Very few investors would stick around in a subpenny stock for 5+ years. This is subpenny land where investors stick around long enough to catch a run, then sell on the bid and pay their 28% STCGT and go with another subpenny ticker.
Yeah, right. He is scrambling trying to find other funding sources since the company has stated in their last filing that they are broke. Maybe he should post something on GoFundMe.
That's exactly right. False assumptions again. Peeps dump their shares, free or not, when they don't believe the ticker is going to have another run. Period.
You too! Sorry your significant other had to leave town ... and leave you alone for Thanksgiving.
Happy Holidays to you and yours as well. Thankfully, a nice thoughtful post.
Which begs the question ... why are they dumping their bonus shares if this ticker has such great prospects? By your logic, they could sell shares on the next run and make a ton of money. Unless they've done their due diligence and realized that they're better off selling.
Not an absurd price at all. And no one is making bank on a stock that has tanked from .0094 to .0002, unless via shorting and selling at the bid repeatedly ... and paying 28% short term capital gains tax on each and every transaction. Not unless someone has a million share inventory to draw from and even then, a sub-penny ticker.
Happy Thanksgiving!
Thank you, Popeye, I will. And you and yours as well.
Doesn't matter, Popeye. That's one day. The PPS has been on the decline the past 6 of 8 days or so. That means more selling into the bid and peeps dumping their shares. Otherwise, we wouldn't be down another 9% or so in heavy trading.
No, he wanted to stop the hemorrhage.
Buying and selling, Popeye. Finished virtually unchanged.
Wow. He decided to make a buy to stop the PPS erosion and prop up the stock.
Now in the trip 2's. Wow, just wow!
https://www.barchart.com/stocks/quotes/ADMD/opinion
What goes up yesterday ... must come slamming back down to reality today on heavy selling.
SSDD with this sad ticker.